Heart Disease News and Research

Latest Heart Disease News and Research

CryoLife files PerClot IDE with FDA to initiate clinical trials in the U.S.

CryoLife, Inc., an implantable biological medical device and cardiovascular tissue processing company, announced today that it has filed an IDE with the United States Food and Drug Administration to begin clinical trials for the purpose of obtaining Pre-Market Approval to distribute PerClot in the U.S. to control bleeding during surgical procedures or following traumatic injuries.

5 Apr 2011

Cardioxyl's CXL-1020 preclinical data against heart failure presented at ACC meeting

Cardioxyl Pharmaceuticals, Inc. announced today that it is presenting two abstracts from studies of its lead clinical candidate, CXL-1020, at the American College of Cardiology's 60th Annual Scientific Session & Expo in New Orleans, Louisiana.

5 Apr 2011

All Children's Hospital joins Johns Hopkins Medicine

All Children's Hospital, in St. Petersburg, Fla., is now a part of the Johns Hopkins Health System (JHHS) and a fully integrated member of Johns Hopkins Medicine (JHM). All Children's is the first U.S. hospital outside of the Baltimore/Washington, D.C., region to become integrated with JHM, which includes the Johns Hopkins University School of Medicine and The Johns Hopkins Hospital and Health System.

4 Apr 2011

Medical industry veteran set to play key role as Microvisk gears up to launch Smartstrip®

Microvisk Technologies, the developer of a handheld system to monitor the blood clotting status of patients taking the drug Warfarin, today announced that it has strengthened its Board with the appointment of medical industry veteran, Bill Moffitt, as Chairman and Peter Whitehouse as CFO.

4 Apr 2011

Study reveals increased incidence of major adverse cardiac events in patients with severe psoriasis

Psoriasis is a common inflammatory skin disease, and if severe, has been demonstrated to be a risk factor for cardiovascular (CV) disease. However, the degree to which psoriasis is associated with major adverse cardiac events (MACE), such as heart attack, stroke, and cardiovascular death has not been defined. Now, new research from the University of Pennsylvania School of Medicine has revealed an increased incidence of MACE in patients with severe psoriasis.

4 Apr 2011

Sigma-Aldrich establishes European Regional Headquarters in Switzerland

Sigma-Aldrich Corporation opened its European Regional Headquarters today in St. Gallen, Switzerland. The new Einstein Facility located in the heart of St. Gallen will be home to approximately 50 employees.

4 Apr 2011

Sofie Biosciences launches GENISYS4 benchtop small animal PET system

Sofie Biosciences, a developer of molecular imaging systems and agents, announced the launch of GENISYS4, their new benchtop small animal PET system. Introduced today at the 2011 American Association for Cancer Research Annual Meeting, this compact, preclinical multimodality PET system provides researchers with the ability to non-invasively visualize and measure the biology of disease and therapeutic response over the course of a study.

4 Apr 2011

Coronary computed tomographic angiography to evaluate acute chest pain reduces hospital admissions

Hospital admissions at Stony Brook University Medical Center on Long Island were significantly reduced when using coronary computed tomographic angiography (CCTA) to evaluate patients presenting in the emergency department (ED) with acute chest pain (ACP), according to research results presented during a scientific session at the American College of Cardiology's 60th Annual Scientific Session and Expo in New Orleans on April 3.

4 Apr 2011

FDA approves St. Jude Medical's Safire BLU and Therapy Cool Path irrigated ablation catheters

St. Jude Medical, Inc., a global medical device company, announced today that it has received U.S. Food and Drug Administration (FDA) approval of two new irrigated ablation catheters - the Safire BLU™ Bi-directional Irrigated Ablation Catheter and the Therapy™ Cool Path™ bi-directional ablation catheter.

4 Apr 2011

Vermillion, Quest Diagnostics enter agreement to launch OVA1 IVDMIA assay in India

Vermillion, a molecular diagnostics company, today announced that it has signed an agreement with Quest Diagnostics to make OVA1 available in India. The companies are targeting a launch in the second quarter of 2011. Additionally, at the International Gynecologic Cancer Society (IGCS) regional meeting held in New Delhi April 2-3, 2011, Dr. Fred Ueland presented data demonstrating the high sensitivity for ovarian malignancy of OVA1 in combination with ultrasound.

From Quest Diagnostics 4 Apr 2011

Avanir files IND for NUEDEXTA/AVP-923 Phase II clinical trial for central neuropathic pain in MS patients

Avanir Pharmaceuticals, Inc. today announced that it has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) to begin a large Phase II clinical trial of AVP-923, an investigational drug for the treatment of central neuropathic pain in patients with multiple sclerosis (MS). The FDA has acknowledged receipt of the submission and the company expects that the IND filing will be subject to standard 30-day review.

4 Apr 2011

First Edition: April 4, 2011

Today's health policy news coverage includes reports about Republican lawmakers' plans to make dramatic changes to Medicare and Medicaid as they seek to cut $4 trillion from the budget over the next 10 years.

4 Apr 2011

Aspirin usage associated with decrease in pancreatic cancer risk

The use of aspirin at least once per month is associated with a significant decrease in pancreatic cancer risk, according to results of a large case-control study presented at the AACR 102nd Annual Meeting 2011, held here April 2-6.

4 Apr 2011

Esaote acquires 3mensio

Esaote International NV and 3mensio Medical Imaging BV have entered into an agreement pursuant to which Esaote acquires 3mensio in order to expand its leading role in healthcare information technology.

4 Apr 2011

Stealth announces Bendavia Phase I clinical study results against ischemia reperfusion injury

Stealth Peptides Inc., a privately held biopharmaceutical company developing innovative therapies, announced today the results of a healthy volunteers Phase I clinical study of Bendavia™, a novel compound that targets the mitochondrion to treat ischemia reperfusion injury.

4 Apr 2011

Abiomed presents Impella PROTECT II study final results in PCI at ACC and i2 Summit

Abiomed, Inc., a leading provider of breakthrough heart support technologies, today announced the final results from the PROTECT II study, presented by William O'Neill, M.D., Dean of University of Miami and Principal Investigator of PROTECT II, at the American College of Cardiology's 60th Annual Scientific Session and i2 Summit 2011 in New Orleans.

4 Apr 2011

Abbott's XIENCE V Coronary Stent System data presented at ACC meeting

A pooled analysis of the SPIRIT II, III, IV and COMPARE trials presented today further reinforces the positive clinical performance of Abbott's market-leading XIENCE V Everolimus Eluting Coronary Stent System.

4 Apr 2011

BSX presents ION and TAXUS Stent trial data against coronary artery disease at ACC meeting

Boston Scientific Corporation today announced results from a pooled patient-level analysis of its PERSEUS and TAXUS ATLAS clinical trial data, demonstrating differences in safety and efficacy outcomes favoring the next-generation ION Platinum Chromium Paclitaxel-Eluting Stent System compared to the currently available TAXUS Liberte Paclitaxel-Eluting Stent System.

4 Apr 2011

Men who consume digoxin have 24% reduced risk of prostate cancer

Johns Hopkins scientists and their colleagues paired laboratory and epidemiologic data to find that men using the cardiac drug, digoxin, had a 24 percent lower risk for prostate cancer. The scientists say further research about the discovery may lead to use of the drug, or new ones that work the same way, to treat the cancer.

4 Apr 2011

Leukemia & Lymphoma publishes CTI's CPOP phase I/II trial results against NHL

Cell Therapeutics, Inc. announced today that the April 2011 edition of the peer reviewed journal, Leukemia & Lymphoma published results of a phase I/II clinical trial evaluating the effect of cyclophosphamide, pixantrone, vincristine, and prednisone in treating patients with aggressive non-Hodgkin's lymphoma who relapsed following initial therapy with cyclophosphamide, doxorubicin, vincristine, and prednisone.

4 Apr 2011

Heart Disease News and Research

Latest Heart Disease News and Research

CryoLife files PerClot IDE with FDA to initiate clinical trials in the U.S.

Cardioxyl's CXL-1020 preclinical data against heart failure presented at ACC meeting

All Children's Hospital joins Johns Hopkins Medicine

Medical industry veteran set to play key role as Microvisk gears up to launch Smartstrip®

Study reveals increased incidence of major adverse cardiac events in patients with severe psoriasis

Sigma-Aldrich establishes European Regional Headquarters in Switzerland

Sofie Biosciences launches GENISYS4 benchtop small animal PET system

Coronary computed tomographic angiography to evaluate acute chest pain reduces hospital admissions

FDA approves St. Jude Medical's Safire BLU and Therapy Cool Path irrigated ablation catheters

Vermillion, Quest Diagnostics enter agreement to launch OVA1 IVDMIA assay in India

Avanir files IND for NUEDEXTA/AVP-923 Phase II clinical trial for central neuropathic pain in MS patients

First Edition: April 4, 2011

Aspirin usage associated with decrease in pancreatic cancer risk

Esaote acquires 3mensio

Stealth announces Bendavia Phase I clinical study results against ischemia reperfusion injury

Abiomed presents Impella PROTECT II study final results in PCI at ACC and i2 Summit

Abbott's XIENCE V Coronary Stent System data presented at ACC meeting

BSX presents ION and TAXUS Stent trial data against coronary artery disease at ACC meeting

Men who consume digoxin have 24% reduced risk of prostate cancer

Leukemia & Lymphoma publishes CTI's CPOP phase I/II trial results against NHL

Innovation in neuroscience drug discovery - eBook eBook

How can super-resolution technology help study neurotransmission?

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Heart Disease News and Research

Latest Heart Disease News and Research

Innovation in neuroscience drug discovery - eBook eBook

How can super-resolution technology help study neurotransmission?

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Newsletters you may be interested in